Literature DB >> 8095457

Tolerance induction by clonal deletion of CD4+8+ thymocytes in vitro does not require dedicated antigen-presenting cells.

H Pircher1, K Brduscha, U Steinhoff, M Kasai, T Mizuochi, R M Zinkernagel, H Hengartner, B Kyewski, K P Müller.   

Abstract

The cellular requirements of T cell tolerance induction in the thymus by clonal deletion was investigated by using an in vitro assay: thymocytes from mice expressing a transgenic TcR specific for lymphocytic choriomeningitis virus (LCMV) and H-2Db were co-cultured with various H-2b cell types as antigen-presenting cells in the presence of the antigenic LCMV peptide. The results revealed that all cell lines examined including embryonic and transformed fibroblasts, melanoma cells, cortical thymic epithelial cells, lymphomas and neuronal cells induced an antigen dose-dependent deletion of CD4+8+ thymocytes. Similarly, highly enriched accessory cell populations from thymus and spleen (macrophages, dendritic and cortical epithelial cells, i.e. thymic nurse cells) could induce antigen-specific depletion of immature CD4+8+ thymocytes. Depending on the cell type examined micromolar to picomolar concentration of LCMV peptide were required to induce deletion. The effectiveness of deletion by the different cell types did not correlate with their major histocompatibility class I expression level; it was, however, influenced by the presence of ICAM-1 adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095457     DOI: 10.1002/eji.1830230315

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  Functional management of an antiviral cytotoxic T-cell response.

Authors:  M F Bachmann; D E Speiser; P S Ohashi
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes.

Authors:  N L Perillo; C H Uittenbogaart; J T Nguyen; L G Baum
Journal:  J Exp Med       Date:  1997-05-19       Impact factor: 14.307

Review 3.  The molecular jury: deciding whether immature thymocytes should live or die.

Authors:  S Vukmanović
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

4.  Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment.

Authors:  Jinhai Wang; Jay Lozier; Gibbes Johnson; Susan Kirshner; Daniela Verthelyi; Anne Pariser; Elizabeth Shores; Amy Rosenberg
Journal:  Nat Biotechnol       Date:  2008-08       Impact factor: 54.908

5.  An acetylcholine receptor alpha subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis.

Authors:  A M Salmon; C Bruand; A Cardona; J P Changeux; S Berrih-Aknin
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

6.  Positive selection of self- and alloreactive CD8+ T cells in Tap-1 mutant mice.

Authors:  C J Aldrich; H G Ljunggren; L Van Kaer; P G Ashton-Rickardt; S Tonegawa; J Forman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

7.  Quantitative impact of thymic clonal deletion on the T cell repertoire.

Authors:  J P van Meerwijk; S Marguerat; R K Lees; R N Germain; B J Fowlkes; H R MacDonald
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

8.  CD2 sets quantitative thresholds in T cell activation.

Authors:  M F Bachmann; M Barner; M Kopf
Journal:  J Exp Med       Date:  1999-11-15       Impact factor: 14.307

9.  Hematopoietic chimerism and transplantation tolerance: a role for regulatory T cells.

Authors:  Lise Pasquet; Olivier Joffre; Thibault Santolaria; Joost P M van Meerwijk
Journal:  Front Immunol       Date:  2011-12-28       Impact factor: 7.561

10.  CD4 T cell tolerance to human C-reactive protein, an inducible serum protein, is mediated by medullary thymic epithelium.

Authors:  L Klein; T Klein; U Rüther; B Kyewski
Journal:  J Exp Med       Date:  1998-07-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.